In today’s recent session, 74.05 million shares of the Silexion Therapeutics Corp (NASDAQ:SLXN) have been traded, and its beta is 0.08. Most recently the company’s share price was $1.45, and it changed around $0.34 or 30.55% from the last close, which brings the market valuation of the company to $12.19M. SLXN at last check was trading at a discount to its 52-week high of $122.02, offering almost -8315.17% off that amount. The share price’s 52-week low was $0.57, which indicates that the recent value has risen by an impressive 60.69% since then.

Silexion Therapeutics Corp stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended SLXN as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.

Silexion Therapeutics Corp (NASDAQ:SLXN) trade information

Instantly SLXN has been showing a green trend so far today with a performance of 30.55% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.7800 on recent trading dayincreased the stock’s daily price by 18.54%. The company’s shares are currently down -27.91% year-to-date, but still up 26.01% over the last five days. On the other hand, Silexion Therapeutics Corp (NASDAQ:SLXN) is -7.70% down in the 30-day period.

Silexion Therapeutics Corp (SLXN) estimates and forecasts

Silexion Therapeutics Corp earnings are expected to increase by 48.89% in 2025, but the outlook is positive 11.11% per year for the next five years.

Silexion Therapeutics Corp (NASDAQ:SLXN)’s Major holders

The former held 587.0 shares worth $842.0, making up 0.03% of all outstanding shares.